{"id":"W2810342468","doi":"10.1001/jamaoncol.2018.1812","title":"Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Bausch Health (Canada); London Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Metastatic breast cancer; Taxane; Internal medicine; Adverse effect; Breast cancer; Pharmacokinetics; Oncology; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Capecitabine; Gastroenterology; Pharmacology; Progressive disease; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000597553,0.0003237587,0.0008998061,0.0002999347,0.0001019024,0.0000271537,0.0002594642,0.0001938114,0.002093082],"category_scores_gemma":[0.0002441479,0.0002570119,0.00007123583,0.001004396,0.0007290912,0.000179502,0.0001045751,0.0008035024,0.0001973724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001891719,"about_ca_system_score_gemma":0.003271229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001896861,"about_ca_topic_score_gemma":0.01225003,"domain_scores_codex":[0.9969932,0.0003697681,0.000521815,0.0006676789,0.0005530389,0.0008945319],"domain_scores_gemma":[0.9976542,0.0005241146,0.0001828306,0.0005234793,0.0007594021,0.0003559607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.06176285,0.00739858,0.1250909,0.00106195,0.00126712,0.00644448,0.01153335,0.00008649291,0.03291227,0.001242523,0.04656032,0.7046392],"study_design_scores_gemma":[0.03933163,0.03475713,0.8255426,0.002024311,0.0004005368,0.002508419,0.002980037,0.0008116039,0.009208158,0.0003481608,0.08122258,0.0008648823],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.932335,0.0004042556,0.0001684881,0.03979486,0.0005104773,0.001940884,0.0001964744,0.0001096114,0.02453992],"genre_scores_gemma":[0.9876527,0.0001884541,0.004045174,0.005353951,0.0005134426,0.0005633305,0.00005509436,0.00008678227,0.001541037],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7037743,"threshold_uncertainty_score":0.9999882,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02518294945205386,"score_gpt":0.3936798830373113,"score_spread":0.3684969335852575,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}